An important unresolved question is how the programs to generate primitive (embryonic) and definitive(adult) erythroid cells differ. This has clinical relevance for sickle cell anemia, which can be ameliorated byreactivation of a primitive erythroid program. A novel protocol has been developed to isolate stage-specificmouse primary erythroid cells using laser capture microdissection (LCM), followed by microarray expressionassays. By identifying genes that are differentially expressed in primitive and definitive cells, we will generatetestable hypotheses about genes that control erythroid development. The raw microarray data will be widelydisseminated, and we will test the functions of prioritized candidate genes. The feasibility and reproducibilityof these techniques has been established using the rarest type of erythroid cells, purified from mouseembryonic day 9 (E9) yolk sac tissue sections. In mouse expression arrays, 98 genes are expressedsignificantly higher in E9 erythroid than in control E9 epithelial cells. In our Preliminary Studies and the workof others, candidate regulators of primitive erythropoiesis include Rnd2, Slit 2, reelin and LM02, andmembers of the BMP, VEGF and retinoid signaling pathways.
Aim 1 is to complete the genetic profile ofmouse erythroid development, using RNA from highly purified, temporally-staged cells from fetal liver andbone marrow in hybridizations to mouse oligonucleotide microarrays. This will complement our data forembryonic yolk sac. Differentially expressed transcription factor, chromatin regulatory, cell surface receptor,cell growth and signaling genes will be of high priority for study. Among the statistical analyses, supervisedlearning methods will identify genes that behave similarly to the developmental^ controlled globin genes.The observed erythroid- and developmental stage-specific expression of selected, high priority candidategenes will be verified using quantitative RT-PCR, and testable hypotheses about the control mechanisms ofprimitive and definitive erythropoiesis will be generated.
In Aim 2, genes differentially expressed due to theabsence of KLF2, a transcription factor essential for primitive erythropoiesis, are being identified. RNA fromLCM-isolated erythroid cells from KLF2-/- E9 yolk sacs is being used in microarray assays to compare thegene expression profile to that of wild-type cells.
In Aim 3, the hypotheses generated about genes controllingprimitive erythropoiesis will be tested using existing knockout mice and knockdowns in erythroid cell lines.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54HL090516-01
Application #
7458464
Study Section
Special Emphasis Panel (ZHL1-CSR-O (F1))
Project Start
2008-06-18
Project End
2012-03-31
Budget Start
2008-06-18
Budget End
2009-03-31
Support Year
1
Fiscal Year
2008
Total Cost
$224,562
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Smith, Wally R; McClish, Donna K; Dahman, Bassam A et al. (2015) Daily home opioid use in adults with sickle cell disease: The PiSCES project. J Opioid Manag 11:243-53
Ameringer, Suzanne; Elswick Jr, R K; Smith, Wally (2014) Fatigue in adolescents and young adults with sickle cell disease: biological and behavioral correlates and health-related quality of life. J Pediatr Oncol Nurs 31:6-17
Redmond, Latasha C; Pang, Christopher J; Dumur, Catherine et al. (2014) Laser capture microdissection of embryonic cells and preparation of RNA for microarray assays. Methods Mol Biol 1092:43-60
Alsalman, Abdulkhaliq J; Smith, Wally R (2013) Expanding the framework of assessing adherence and medication-taking behavior. J Pain Palliat Care Pharmacother 27:114-24
Dampier, Carlton D; Smith, Wally R; Wager, Carrie G et al. (2013) IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies. Clin Trials 10:319-31
Dampier, Carlton D; Wager, Carrie G; Harrison, Ryan et al. (2012) Impact of PCA strategies on pain intensity and functional assessment measures in adults with sickle cell disease during hospitalized vaso-occlusive episodes. Am J Hematol 87:E71-4
Pang, Christopher J; Lemsaddek, Wafaa; Alhashem, Yousef N et al. (2012) Kruppel-like factor 1 (KLF1), KLF2, and Myc control a regulatory network essential for embryonic erythropoiesis. Mol Cell Biol 32:2628-44
Peters-Lawrence, Marlene H; Bell, Margaret C; Hsu, Lewis L et al. (2012) Clinical trial implementation and recruitment: lessons learned from the early closure of a randomized clinical trial. Contemp Clin Trials 33:291-7
Dampier, Carlton D; Smith, Wally R; Kim, Hae-Young et al. (2011) Opioid patient controlled analgesia use during the initial experience with the IMPROVE PCA trial: a phase III analgesic trial for hospitalized sickle cell patients with painful episodes. Am J Hematol 86:E70-3
Sogutlu, Aslihan; Levenson, James L; McClish, Donna K et al. (2011) Somatic symptom burden in adults with sickle cell disease predicts pain, depression, anxiety, health care utilization, and quality of life: the PiSCES project. Psychosomatics 52:272-9

Showing the most recent 10 out of 23 publications